Business · 04/09/2014Updated: 10/17/2026 · 1 min read
FDA Establishes Public Docket for Duchenne Muscular Dystrophy Drug Development Guidance
Summary
The FDA is seeking public comment on a proposed draft guidance for the development of drugs for Duchenne muscular dystrophy, following a proposal submitted by Parent Project Muscular Dystrophy and other stakeholders in 2014.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →